MedPath

Improving Muscle Function in Nutritionally at Risk, Elderly Patients

Not Applicable
Withdrawn
Conditions
ICU-acquired Weakness
Muscle Weakness
Interventions
Dietary Supplement: Nutritional Supplement
Dietary Supplement: HMB protein supplement (3g)
Registration Number
NCT03071354
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

The investigators propose to conduct a randomized, control trial of β-hydroxy-β-methylbutyrate (HMB) supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by ICU-specific nutritional risk scores. Patients will receive either 3g of HMB daily, or control, daily until day 28 following randomization (even if discharged).The investigators will measure functional outcomes using standard, validated measures prior and after discharge.

Detailed Description

The investigators propose to conduct a randomized, control trial of HMB supplementation in elderly patients (≥65 years of age) with acute respiratory failure, who are identified at high risk for malnutrition by ICU-specific nutritional risk scores. Patients will receive either 3g of HMB daily, or control, daily until day 28 following randomization (even if discharged).the investigators will measure functional outcomes using standard, validated measures prior and after discharge.

The investigators hypothesize that this inexpensive nutrient, HMB, along with our supportive measures, reduces muscle loss, improves physical muscle function, and improves quality of life in the longer term following critical illness.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Patients age ≥65 years.
  2. Acute respiratory failure (ARF, defined by expected mechanical ventilation for > 72 hours from the point of screening)
  3. Elevated nutritional risk (NUTRIC score>5 - see below).
Read More
Exclusion Criteria
  1. Over 72 hours from ICU admission.
  2. Not expected to survive another 48 hours
  3. Lack of commitment to full, aggressive care
  4. Patients who have an absolute contraindication to EN (obstruction, perforation, high output fistula),
  5. Pregnant women
  6. Prisoners
  7. Known allergy to study nutrients
  8. Unable to walk prior to current illness.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control GroupNutritional SupplementControl patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study. In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards.
HMB Protein Supplementation GroupHMB protein supplement (3g)Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study. In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards.
Primary Outcome Measures
NameTimeMethod
6 minute walk distanceAt 42 days follow up

Maximum distance walked by subject in 6 minutes on level ground

Secondary Outcome Measures
NameTimeMethod
Body Composition-Quadriceps layer muscle thickness (QLMT)At 42 days follow up

Thigh ultrasound for quadriceps muscle thickness

Body Composition-Calf circumferenceAt 42 days follow up

Measurement of the calf circumference

Timed Get Up and Go testAt 42 days follow up

Time for subject to go from sitting to standing unaided

Hand-grip strength (HGS)At 42 days follow up

Measurement of force of isometric grip strength using hand-held dynamometer

Trial Locations

Locations (1)

Wake Forest Baptist Medical Center

🇺🇸

Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath